Mga Batayang Estadistika
| LEI | 549300EI6OKH5K5Q2G38 |
| CIK | 1682852 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Moderna, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 1, 2025 |
Exhibit 99.1 Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quar |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 1, 2025 |
Exhibit 99.1 Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion Announces reduction of $1.4 to $1.7 billion in estimated GAAP operating costs |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| February 21, 2025 |
Moderna, Inc. Insider Trading Policy Exhibit 19 MODERNA, INC. INSIDER TRADING POLICY Securities laws prohibit anyone who is aware of material nonpublic information about a company from trading (i.e., buying, selling or otherwise transacting) in securities (such as stock) of that company, commonly known as “insider trading.” These laws also prohibit anyone who is aware of material nonpublic information from disclosing that information |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| February 21, 2025 |
As filed with the Securities and Exchange Commission on February 21, 2025 As filed with the Securities and Exchange Commission on February 21, 2025 Registration No. |
|
| February 21, 2025 |
Calculation of Filing Fee Tables S-8 Moderna, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock Other 15,420,946 $ 31.12 $ 479,899,839.52 0.0001531 $ 73,472.67 Total Offering Amounts: $ 479,899,839.52 $ |
|
| February 21, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES Moderna, Inc.’s principal affiliates as of December 31, 2024, are listed below. All other affiliates, if considered in the aggregate as a single affiliate, would not constitute a significant subsidiary. Subsidiary Jurisdiction of Incorporation Moderna Australia Pty Ltd Australia Moderna Biopharma Canada Corporation Canada Moderna Biotech Distributor UK Ltd. United Kingdom |
|
| February 21, 2025 |
EXHIBIT 4.2 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Moderna, Inc. (“us,” “our,” “we” or the “Company”) is a summary of the rights of our common stock and certain provisions of our restated certificate of incorporation (our “charter”) and our second amended and restated by-laws (our “by-laws”). This summary does not purport to be complete and is qualified in i |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 14, 2025 |
Exhibit 99.1 Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing Reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP d |
|
| January 13, 2025 |
Exhibit 99.1 Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) Updates 2025 expected revenue range to $1.5 to 2.5 billion Expects to reduce 2025 cash cost expenses by $1.0 billion with a plan for additional 2026 cost reduc |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 7, 2024 |
Exhibit 99.1 Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billion Initiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mR |
|
| November 7, 2024 |
2018 Employee Stock Purchase Plan. Exhibit 10.1 MODERNA, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Moderna, Inc. 2018 Employee Stock Purchase Plan (“the Plan”) is to provide eligible employees of Moderna, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). An aggregate of 810, |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| October 2, 2024 |
Exhibit 99.1 Abbas Hussain Joins Moderna’s Board of Directors Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor Pharma As former Global President of GSK, Pharmaceuticals and Vaccines, Hussain brings significant global vaccine commercialization experience in emerging and mature markets, along with significant Boa |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 12, 2024 |
Exhibit 99.1 Moderna R&D Day Highlights Progress and Strategic Priorities Focuses on ten product approvals through 2027 Expects to submit next-generation COVID vaccine for approval in 2024 Expects to submit flu/COVID combination vaccine for approval in 2024 Announces positive Phase 3 results for its RSV vaccine for high-risk adults aged 18 to 59; expects to submit sBLA for U.S. approval in 2024 An |
|
| September 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 29, 2024 |
144 0001760669 XXXXXXXX LIVE 0001682852 Moderna, Inc. 001-38753 325 BINNEY STREET CAMBRIDGE MA 02142 6177146500 Hoge Stephen Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 300 23407.80 384396030 08/29/2024 NASDAQ Common 08/28/2024 Restricted Stock Vesting Issuer N 300 08/28/2024 Compensation N Stephen Hoge 325 Binney Street Cambridge MA 02142 Common 05/29/2024 |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 1, 2024 |
Exhibit 99.1 Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33) Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion Received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positi |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| July 23, 2024 |
Exhibit 99.1 David Rubenstein Joins Moderna’s Board of Directors Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry investor experience and global policy expertise, replacing retiring director Stephen Berenson Co-founder and director Robert Langer also to retire from the Moderna Board; recruitment efforts ongoing for his replacement CAMBRIDGE, Massachusetts / July 23, 2024 / Mod |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 9, 2024 |
Restated Certificate of Incorporation of Moderna, Inc. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF MODERNA, INC. Moderna, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Moderna, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was July 22, 2016 (the |
|
| May 9, 2024 |
Second Amended and Restated By-laws of Moderna, Inc. Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS OF MODERNA, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by or in the manner determined by the Board of Directors of |
|
| May 2, 2024 |
Exhibit 99.1 Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion Initiated three new clinical studies evaluating Moderna’s |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 10, 2024 |
MRNA / Moderna, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0021-modernainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Moderna Inc Title of Class of Securities: Common Stock CUSIP Number: 60770K107 Date of Event Which Requires Filing of this Statement: March 28, 2024 Check the appropriate box to designate the rule pursua |
|
| March 21, 2024 |
Notice of Annual Meeting of Shareholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| March 21, 2024 |
COURTESY PDF OF PROXY STATEMENT Table of contents 2 Proxy Summary 8 Proposal No. 1: Election of Directors 14 Governance 26 Director Compensation 28 Certain Relationships and Related Party Transactions 29 ESG Topics 33 Management 35 Proposal No. 2: Nonટ binding Advisory Vote to Approve the Compensation of our Named Executive Officers 36 Letter from the Compensation and Talent Committee 38 Executive Compensation 73 Compensation and |
|
| March 11, 2024 |
Notice of Annual Meeting of Shareholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| February 23, 2024 |
Amended and Restated By-laws of the Registrant. Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS OF MODERNA, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by or in the manner determined by the Board of Directors of |
|
| February 23, 2024 |
Exhibit 10.15 Personal and Confidential December 8, 2023 (As revised on December 30, 2023) VIA ELECTRONIC MAIL [***] Arpa Garay [***] [***] Re: Executive Separation and Transitional Services Agreement (Please sign and return page 9 by January 4, 2024; sign and return Exhibit A by the later of the Separation Date or January 4, 2024) Dear Arpa, In accordance with the Amended and Restated Executive S |
|
| February 23, 2024 |
Form of Employee Restricted Stock Unit Award Agreemen Exhibit 10.22 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE MODERNA, INC. 2018 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: [Participant Name] No. of Restricted Stock Units: [Number of Shares Granted] Grant Date: [Grant date] Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Moderna, Inc. (the “Company”) |
|
| February 23, 2024 |
Form of Employee Non-Qualified Stock Option Agreement. Exhibit 10.23 NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER THE MODERNA, INC. 2018 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: [Participant Name] No. of Option Shares: [Number of Shares Granted] Option Exercise Price per Share: $[Grant Price] Grant Date: [Grant date] Expiration Date: [Expiration Date] Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as am |
|
| February 23, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES Moderna, Inc.’s principal affiliates as of December 31, 2023, are listed below. All other affiliates, if considered in the aggregate as a single affiliate, would not constitute a significant subsidiary. Subsidiary Jurisdiction of Incorporation Moderna Australia Pty Ltd Australia Moderna Biopharma Canada Corporation Canada Moderna Biotech Distributor UK Ltd. United Kingdom |
|
| February 23, 2024 |
2018 Employee Stock Purchase Plan. Exhibit 10.21 MODERNA, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Moderna, Inc. 2018 Employee Stock Purchase Plan (“the Plan”) is to provide eligible employees of Moderna, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). An aggregate of 810 |
|
| February 23, 2024 |
As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration No. |
|
| February 23, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Moderna, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par value |
|
| February 23, 2024 |
, Inc. Policy for Recoupment of Executive Incentive Com Exhibit 97 Moderna, Inc. Policy for Recoupment of Executive Incentive Compensation Definitions As used herein, the following terms have the following meanings: “Board” means the Board of Directors of the Company. “Clawback Period” means the three completed fiscal years immediately preceding the date that the Company is required to prepare a Financial Restatement. “Company” means Moderna, Inc. “Com |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 22, 2024 |
Exhibit 99.1 Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55 Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion rel |
|
| February 13, 2024 |
MRNA / Moderna, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01471-modernainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Moderna Inc Title of Class of Securities: Common Stock CUSIP Number: 60770K107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pu |
|
| February 7, 2024 |
MRNA / Moderna, Inc. / Bancel Stephane - SC 13G/A Passive Investment SC 13G/A 1 d752423dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934* (Amendment No. 5) Moderna, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 60770K 107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 8, 2024 |
Exhibit 99.1 Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference Company announces product sales for 2023 of approximately $6.7 billion (unaudited); U.S. COVID-19 market share season to date increased to 48% in 2023, up from 37% in 2022 Company reiterates 2024 expected product sales of approximately $4 billion, planned return to sales growth in 2025 and |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 2, 2023 |
Exhibit 99.1 Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion Spikevax U.S. market share to date increased to 45% from 36% in 2022 Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025 Company has significantly improved future cost |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 11, 2023 |
Exhibit 99.1 Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s mRNA technology for the development of novel cancer vaccines Collaboration |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| August 3, 2023 |
Exhibit 99.1 Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62 Company expecting 2023 COVID-19 vaccine sales of $6 billion to $8 billion, dependent on U.S. vaccination rates Company submitted its investigational RSV vaccine to several regulators globally ahead of pot |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 5, 2023 |
EX-4.4 Exhibit 4.4 MODERNA, INC. TO Trustee Indenture Dated as of , 20 Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE ONE - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 101. Definitions 1 SECTION 102. Compliance Certificates and Opinions 9 SECTION 103. Form of Documents Delivered to Trustee 9 SECTION 104. Acts of Holders 10 SECTION 105. Notices, etc., to Trustee a |
|
| May 5, 2023 |
As filed with the Securities and Exchange Commission on May 5, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 5, 2023 Registration No. |
|
| May 5, 2023 |
Form of indenture for senior debt securities and the related form of senior debt security. EX-4.3 Exhibit 4.3 MODERNA, INC. TO Trustee Indenture Dated as of , 20 Senior Debt Securities TABLE OF CONTENTS Page ARTICLE ONE - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 SECTION 101. Definitions 2 SECTION 102. Compliance Certificates and Opinions 8 SECTION 103. Form of Documents Delivered to Trustee 9 SECTION 104. Acts of Holders 9 SECTION 105. Notices, etc., to Trustee and Comp |
|
| May 5, 2023 |
U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| May 4, 2023 |
Exhibit 99.1 Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19 Company in negotiations for new orders for fall of 2023 in U.S., Japan, and E.U., in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously announced C |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| April 28, 2023 |
April 28, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D. |
|
| April 14, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 13, 2023 |
Notice of Exempt Solicitation Name of Registrant: Moderna Name of Person Relying on Exempt Solicitation: Oxfam America Address of Person Relying on Exempt Solicitation: 77 North Washington Street, Suite 5-1, Boston, MA 02114 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Prox |
|
| March 15, 2023 |
COURTESY PDF OF PROXY STATEMENT Table of contents 7 Proposal No. 1 Election of Directors 11 Governance 23 Director Compensation 26 Certain Relationships and Related Party Transactions 28 ESG Topics 32 Management 35 Proposal No. 2 Non-binding Advisory Vote to Approve the Compensation of our Named Executive Officers 36 Executive Compensation 69 Compensation and Talent Committee Report 70 Security Ownership of Certain Beneficial Ow |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| February 24, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Brizo Ltd. Bermuda Moderna Australia Pty Ltd Australia Moderna Austria GmbH Austria Moderna Belgium SRL Belgium Moderna Biopharma Canada Corporation Canada Moderna Biotech Distributor UK Ltd. United Kingdom Moderna Biotech Ireland Limited Ireland Moderna Biotech Kenya Manufacturing Ltd. Kenya Moderna Biotech Manufacturing UK Ltd. U |
|
| February 24, 2023 |
Exhibit 10.11 Moderna, Inc. Amended and Restated Executive Severance Plan 1.Purpose. Moderna, Inc. (the “Company”) considers it essential to the best interests of the Company to foster the continuous employment of key management employees. The Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many corporations, the possibility of an involuntary terminat |
|
| February 24, 2023 |
Offer Letter by and between ModernaTX, Inc. and Arpa Garay, dated as of April 21, 2022 Exhibit 10.16 200 Tech Square • Cambridge, MA 02139 phone 617-714-6500 • fax 617-583-1998 April 21, 2022 VIA ELECTRONIC MAIL Arpa Garay [***] [***] Re: Offer of Employment with Moderna Dear Arpa: On behalf of Moderna (ModernaTx, Inc. or, alternatively, one of its US-based subsidiaries to which you may be assigned, hereafter “Moderna” or the “Company”), it is my privilege to offer you the opportuni |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 23, 2023 |
Exhibit 99.1 Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61 Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12 Company reiterating approximately $5 billion in COVID-19 sales contracted |
|
| February 10, 2023 |
MRNA / Moderna Inc / Bancel Stephane - SC 13G/A Passive Investment SC 13G/A 1 d432949dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934* (Amendment No. 4) Moderna, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 60770K 107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 9, 2023 |
MRNA / Moderna Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Moderna Inc. Title of Class of Securities: Common Stock CUSIP Number: 60770K107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| January 9, 2023 |
Exhibit 99.1 Moderna Announces Advances Across mRNA Pipeline and Provides Business Update COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited) Reiterating 2023 expected minimum COVID-19 vaccine sales of approximately $5.0 billion; continue to expect additional contracts for 2023 Company continues to scale with 48 programs in development, including 36 in ongoing clinical studies, |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 3, 2023 |
Deliver the greatest possible impact to people through mRNA medicines. Exhibit 99.1 January 3, 2023 Cambridge, Mass., USA Dear fellow shareholders, When the world was disrupted by a global pandemic, a new technology played a critical role in protecting and restoring human health. Bringing hope during a time of suffering. Bringing relief during a time of anxiety. That technology was mRNA. mRNA is a very special molecule in the body. It exists there, hundreds of thousa |
|
| January 3, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 13, 2022 |
Exhibit 99.1 Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA® (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRU |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 3, 2022 |
Exhibit 10.3 Certain confidential portions of this exhibit have been omitted and replaced with ?[***].? Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private and confidential. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 16 2. AMENDMENT/MODIFI |
|
| November 3, 2022 |
Exhibit 99.1 Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates Third quarter 2022 revenues of $3.4 billion; GAAP net income of $1.0 billion and GAAP diluted EPS of $2.53 Revenue from advance purchase agreements for anticipated delivery in 2022 expected to be $18 to $19 billion, following delay of certain deliveries into 2023 due to short-term supply constraints Pri |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| November 3, 2022 |
Amended and Restated Non-Employee Director Compensation Policy, effective October 1, 2022. ( Exhibit 10.1 Moderna, Inc. Amended and Restated Non-Employee Director Compensation Policy The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the ?Policy?) of Moderna, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employ |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 3, 2022 |
Offer Letter by and between ModernaTX, Inc. and James Mock, dated as of August 15, 2022. ( Exhibit 10.2 August 15, 2022 VIA ELECTRONIC MAIL ([***]) James Mock [***] [***] Re: Offer of Employment with Moderna Dear Jamey, On behalf of Moderna (ModernaTx, Inc. or, alternatively, one of its US-based subsidiaries to which you may be assigned, hereafter ?Moderna? or the ?Company?), it is my privilege to offer you the opportunity to join our mission: to boldly, curiously, and relentlessly deli |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 29, 2022 |
Exhibit 99.1 Moderna Creates New Executive Committee Role Ahead of New Product Launches Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion Jerh Collins Joins Moderna as Chief Technical Operations and Quality Officer to Succeed Juan Andres CAMBRIDGE, Mass.-(ACCESS WIRE)?September 29, 2022- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RN |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 17, 2022 |
JAMES MOCK JOINS MODERNA AS CHIEF FINANCIAL OFFICER EX-99.1 2 d390105dex991.htm EX-99.1 Exhibit 99.1 JAMES MOCK JOINS MODERNA AS CHIEF FINANCIAL OFFICER CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna’s Chief Financial Officer, beginning September 6, 2022. He will serve on Moder |
|
| August 3, 2022 |
Exhibit 99.1 Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates Second quarter 2022 revenues of $4.7 billion; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24 Company reiterates advance purchase agreements for expected delivery in 2022 of approximately $21 billion Company announces new $3 billion share repurchase plan Company has four infectious diseas |
|
| August 3, 2022 |
Amended and Restated Non-Employee Director Compensation Policy, effective April 28, 2022. Exhibit 10.1 Moderna, Inc. Amended and Restated Non-Employee Director Compensation Policy The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the ?Policy?) of Moderna, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employ |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| August 3, 2022 |
Exhibit 10.4 Certain confidential portions of this exhibit have been omitted and replaced with ?[***].? Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 5 2. AMENDMENT/MODIFICA |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 3, 2022 |
Exhibit 10.6 Certain confidential portions of this exhibit have been omitted and replaced with ?[***].? Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private and confidential. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 14 2. AMENDMENT/MODIFI |
|
| June 1, 2022 |
Exhibit 10.1 May 27, 2022 VIA ELECTRONIC MAIL ([***]) Personal and Confidential David Meline [***] [***] Re: Updated Executive Retirement and Strategic Consulting Agreement Dear David: This Updated Executive Retirement and Strategic Consulting Agreement (the ?Agreement?) between you and ModernaTX, Inc. (together with its parents, subsidiaries, and affiliates including Moderna Services, Inc., the ? |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 24, 2022 |
Exhibit 99.1 May 24, 2022 Stock Option Exercise and Charitable Giving Stephane Bancel Chief Executive Officer Dear Stakeholders, When I joined Moderna almost 11 years ago, I was resolute in my belief that mRNA technology would change the world. Through the challenges of the COVID-19 pandemic, we have been able to make a significant contribution to global public health, while also making Moderna in |
|
| May 24, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 13, 2022 |
Executive Separation Agreement and Release, dated May 13, 2022, between ModernaT Exhibit 10.1 May 11, 2022 Personal and Confidential Jorge M. Gomez [***] [***], NC 28207 Re: Executive Separation Agreement and Release To be signed and returned no later than May 18, 2022 Dear Jorge: Following up on discussions yesterday, this letter confirms the ending of your employment with Moderna (ModernaTx, Inc. or, alternatively, one of its US-based subsidiaries to which you may be assigne |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 4, 2022 |
Exhibit 10.4 Certain confidential portions of this exhibit have been omitted and replaced with ?[***].? Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 11 2. AMENDMENT/MODIFIC |
|
| May 4, 2022 |
Exhibit 10.5 Certain confidential portions of this exhibit have been omitted and replaced with ?[***].? Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 5 2. AMENDMENT/MODIFICA |
|
| May 4, 2022 |
Offer Letter by and between ModernaTX, Inc. and Jorge Gomez, dated as of April 6, 2022. Exhibit 10.1 200 Tech Square ? Cambridge, MA 02139 phone 617-714-6500 ? fax 617-583-1998 April 4, 2022 VIA ELECTRONIC MAIL Jorge M. Gomez [***] [***] Re: Offer of Employment with Moderna Dear Jorge: On behalf of Moderna (ModernaTx, Inc. or, alternatively, one of its US-based subsidiaries to which you may be assigned, hereafter ?Moderna? or the ?Company?), it is my privilege to offer you the opport |
|
| May 4, 2022 |
Exhibit 10.2 April 8, 2022 VIA ELECTRONIC MAIL Personal and Confidential David Meline [***] [***] Re: Executive Retirement and Strategic Consulting Agreement Dear David: Under the Offer of Employment dated June 2, 2020 between you and ModernaTX, Inc. (together with its parents, subsidiaries, and affiliates, the ?Company? and, together with you, the ?Parties?), this Executive Retirement and Strateg |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| May 4, 2022 |
Exhibit 99.1 Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates First quarter 2022 revenues of $6.1 billion; GAAP net-income of $3.7 billion and GAAP diluted EPS of $8.58 Moderna reiterates its 2022 signed advance purchase agreements of approximately $21 billion Company expects to have four programs in Phase 3 in the second quarter: Omicron-containing bivalent COVID |
|
| May 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 11, 2022 |
Jorge Gomez Joins Moderna as Chief Financial Officer Exhibit 99.1 Jorge Gomez Joins Moderna as Chief Financial Officer CAMBRIDGE, Mass.?(ACCESS WIRE)?April 11, 2022? Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna?s Executive Committee and report to Chie |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 25, 2022 |
PX14A6G 1 b325220px14a6g.htm Notice of Exempt Solicitation NAME OF REGISTRANT: Moderna NAME OF PERSON RELYING ON EXEMPTION: Oxfam America ADDRESS OF PERSON RELYING ON EXEMPTION: 226 Causeway Street, Boston, MA 02114 Written materials are submitted pursuant to Rule 14(a)-6(g)(1) promulgated under the Securities and Exchange Act of 1934. Submission is not required of this filer under the terms of th |
|
| March 21, 2022 |
Notice of Exempt Solicitation NAME OF REGISTRANT: Moderna NAME OF PERSON RELYING ON EXEMPTION: Oxfam America ADDRESS OF PERSON RELYING ON EXEMPTION: 226 Causeway Street, Boston, MA 02114 Written materials are submitted pursuant to Rule 14(a)-6(g)(1) promulgated under the Securities and Exchange Act of 1934. |
|
| March 9, 2022 | ||
| March 9, 2022 |
DEFA14A 1 lmrna2022def14a.htm MODERNA, INC. - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission o |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Prox |
|
| February 25, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Brizo Ltd. Bermuda Moderna Australia Pty Ltd Australia Moderna Austria GmbH Austria Moderna Biopharma Canada Corporation Canada Moderna Biotech Ireland Limited Ireland Moderna Biotech Securities, Inc. Massachusetts Moderna Biotech Spain, S.L.U. Spain Moderna Biotech UK Limited United Kingdom Moderna Charitable Foundation, Inc. Dela |
|
| February 25, 2022 |
Form of Non-Employee Director Restricted Stock Unit Award Agreement. Exhibit 10.26 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE MODERNA, INC. 2018 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: [Participant Name] No. of Restricted Stock Units: [Number of Shares Granted] Grant Date: [Grant date] Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the ?Plan?), Moderna, Inc. (the ?Compa |
|
| February 25, 2022 |
Consulting Agreement by and between ModernaTX, Inc. and Corinne Le Goff Exhibit 10.18 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (together with the attached Appendix A, B and C, the ?Agreement?), is made by and between ModernaTX, Inc., a Delaware corporation having a place of business at 200 Technology Square, Cambridge, MA 02139, USA (?Moderna?), and Corinne Le Goff, an individual residing at [***] (?Consultant?). This Agreement shall become effective on the last |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| February 25, 2022 |
Form of Employee Non-Qualified Stock Option Agreement. (7) Exhibit 10.25 NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER THE MODERNA, INC. 2018 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: [Participant Name] No. of Option Shares: [Number of Shares Granted] Option Exercise Price per Share: $[Grant Price] Grant Date: [Grant date] Expiration Date: [Expiration Date] Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as am |
|
| February 25, 2022 |
Exhibit 10.40 Certain confidential portions of this exhibit have been omitted and replaced with ?[***].? Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 12 2. AMENDMENT/MODIFI |
|
| February 25, 2022 |
Form of Non-Employee Director Non-Qualified Stock Option Agreement. Exhibit 10.27 NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE MODERNA, INC. 2018 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: [Participant Name] No. of Option Shares: [Number of Shares Granted] Option Exercise Price per Share: [Grant Price] Grant Date: [Grant date] Expiration Date: [Expiration Date] Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan a |
|
| February 25, 2022 |
Executive Separation and Transitional Services Agreement Exhibit 10.17 200 Technology Square ? Cambridge, MA 02139 phone 617-714-6500 ? fax 617-583-1998 Personal and Confidential November 11, 2021 Corinne Le Goff [***] [***] Re: Executive Separation and Transitional Services Agreement Dear Corinne: In accordance with the Amended and Restated Executive Severance Plan (the ?Severance Plan?) of Moderna Inc. (individually, and together with any direct and i |
|
| February 25, 2022 |
Exhibit 10.34 Certain confidential portions of this exhibit have been omitted and replaced with ?[***].? Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 3 2. AMENDMENT/MODIFIC |
|
| February 25, 2022 |
Offer Letter by and between ModernaTX, Inc. and Corin Exhibit 10.16 December 28, 2020 Corinne Le Goff, Pharm. D., MBA [***] [***] Re: Offer of Employment by ModernaTX, Inc. Dear Corinne, ModernaTX, Inc. (together with its affiliates, the "Company") is pleased to confirm, contingent on receiving appropriate references and the successful completion of a background check/drug screen, its offer to employ you as Chief Commercial Officer, reporting to the |
|
| February 25, 2022 |
Employment Letter Agreement between ModernaTX, Inc. and Shannon Klinger, dated as of March 4, 2021. Exhibit 10.19 March 4, 2021 Shannon Thyme Klinger [***] [***] [***] Re: Employment Letter Agreement Between ModernaTX, Inc. and Shannon Klinger Dear Shannon, ModernaTX, Inc. (together with its affiliates, the ?Company?) is pleased to enter into this Employment Letter Agreement (?Agreement?) regarding your employment as Chief Legal Officer, reporting to the Chief Executive Officer. You shall have a |
|
| February 25, 2022 |
Form of Employee Restricted Stock Unit Award Agreement. (7) Exhibit 10.24 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE MODERNA, INC. 2018 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: [Participant Name] No. of Restricted Stock Units: [Number of Shares Granted] Grant Date: [Grant date] Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the ?Plan?), Moderna, Inc. (the ?Company?) |
|
| February 25, 2022 |
and Omnibus Amendment, dated December 30, 2021, to Exhibit 10.12 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this "Third Amendment") is made as of September 11, 2018, by and between ARE-MA REGION NO. 64, LLC, a Delaware limited liability company ("Landlord"), and MODERNA, INC., a Delaware corporation ("Tenant"). RECITALS A.Tenant and Landlord are now parties to that certain Net Lease dated as of August 29, 2016 ("Original Lease"), as a |
|
| February 24, 2022 |
Exhibit 99.1 Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29 Moderna increased its 2022 signed advance purchase agreements to approximately $19 b |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 14, 2022 |
MRNA / Moderna Inc / Flagship Ventures Fund IV General Partner LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Moderna, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 60770K 10 7 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2022 |
MRNA / Moderna Inc / Bancel Stephane - SC 13G/A Passive Investment SC 13G/A 1 d283352dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934* (Amendment No. 3) Moderna, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 60770K 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 10, 2022 |
MRNA / Moderna Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Moderna Inc. Title of Class of Securities: Common Stock CUSIP Number: 60770K107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 1 |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 10, 2022 |
Exhibit 99.1 Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update 807 million doses of Moderna?s COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries Product sales for 2021 approximately $17.5 billion (unaudited) Increasing APAs for 2022 delivery to approximately $18.5 billion and approx |
|
| January 4, 2022 |
January 4, 2022 Cambridge, Mass., USA Dear fellow shareholders, 2021 was a year of monumental impact and change for Moderna. After a decade of pioneering the development of our mRNA platform, we were ready and well-positioned to play a critical role in combating the COVID-19 pandemic globally with our mRNA vaccine. Our COVID-19 vaccine has been granted emergency use authorization (EUA) or emergenc |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| November 4, 2021 |
Exhibit 10.1 Certain confidential portions of this exhibit have been omitted and replaced with ?[***].? Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICA |
|
| November 4, 2021 |
Exhibit 99.1 Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates Q3 total revenue of $5.0 billion, net income of $3.3 billion and diluted EPS of $7.70 U.S. FDA granted Priority Review to the Biologics License Application for Moderna?s COVID-19 vaccine Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 4, 2021 |
Exhibit 10.2 Certain confidential portions of this exhibit have been omitted and replaced with ?[***].? Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 5 2. AMENDMENT/MODIFICA |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| August 5, 2021 |
Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 13 2. AMENDMENT/MODIFICATION NO. P00008 3 |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 5, 2021 |
Exhibit 99.1 Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2 Dosing started in Ph |
|
| August 5, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 29 2. AMENDMENT/MODIFICATION NO. P00004 3 |
|
| July 12, 2021 |
MRNA / Moderna Inc / BlackRock Inc. Passive Investment us60770k1079071021.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) MODERNA, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 60770K107 - (CUSIP Number) June 30, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| May 6, 2021 |
Exhibit 99.1 Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates SARS-CoV-2 Variant Booster Program Update: Single booster dose of 50 ?g of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two Variants of Concern (B.1.351, P.1) in previously vaccinated clinical trial participants TeenCOVE Study Update:Initial analysis of the |
|
| May 6, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1 CONTRACT ID CODE PAGE OF PAGES 1 | 3 2. AMENDMENT/MODIFICATION NO. P00006 3 |
|
| May 6, 2021 |
Exhibit 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE MODERNA, INC. 2018 STOCK OPTION AND INCE |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 6, 2021 |
Amended and Restated Non-Employee Director Compensation Policy, effective April 28, 2021 Exhibit 10.4 Moderna, Inc. Amended and Restated Non-Employee Director Compensation Policy The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the ?Policy?) of Moderna, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employ |
|
| May 6, 2021 |
Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1 CONTRACT ID CODE PAGE OF PAGES 1 | 10 2. AMENDMENT/MODIFICATION NO. P00007 |
|
| April 29, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2021 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 13, 2021 |
Exhibit 99.1 Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day Phase 3 COVE Study: Updated cases show continued strong efficacy, including greater than 90% against cases of COVID-19 and greater than 95% against severe cases of COVID-19, with approximately 6 months median follow-up post dose 2 Antibody persistence data out to 6 months publishe |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Prox |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Prox |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 10, 2021 |
- COURTESY PDF OF PROXY STATEMENT begin 644 lmrn2021def14a.pdf M)5!$1BTQ+C0-)>+CS],-"C(Y-B P(&]B:@T\/"],:6YE87)I>F5D(#$O3" W M,#0W,#0O3R R.3DO12 Q.30Q,"].(#8V+U0@-CDX-C8X+T@@6R X-38@,34S M-ET^/@UE;F1O8FH-(" @(" @(" @(" @( UXQ7,<#, 9I)AS? M:X0 G''QL)(+VT3L3X-/I:Y+U6T83CLWIP9-YQIY+2'W^3D\0]!VSIV08]R2 MX!8TC*?4Q*W[(#(SJ!=]EYNS?/<[-;PIEO(4^0^LA"UH3V\$<2*5"/MJ#B0 MN3(1U2,%R&..G9>!3 0[T!3^&73N['W($B03N8RC-R*Y;25?K:G-/;+U:K]Q7J6:V0'= M%E |
|
| February 26, 2021 |
EXHIBIT 4.3 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Moderna, Inc. (?us,? ?our,? ?we? or the ?Company?) is a summary of the rights of our common stock and certain provisions of our amended and restated certificate of incorporation and our amended and restated bylaws currently in effect. This summary does not purport to be complete and is qualified in its entir |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| February 26, 2021 |
Exhibit 10.17 AMENDED AND RESTATED EXECUTIVE RETENTION AGREEMENT This Amended and Restated Executive Retention Agreement (this ?Agreement?) is entered into effective as of February 23, 2021 (the ?Effective Date?) between Tal Zaks, M.D. (the ?Executive?) and Moderna, Inc. (the ?Company,? together with Executive, the ?Parties?). WHEREAS, the Executive currently serves as the Company?s Chief Medical |
|
| February 26, 2021 |
W911QY20C0100 (dsoto21610) Page 1 of 31 1. CONTRACT ID CODE PAGE OF PAGES 1 31 2. AMENDMENT/MODIFICATION NO. P00003 3. EFFECTIVE DATE 11-Dec-2020 4. REQUISITION/PURCHASE REQ. NO. SEE SCHEDULE 5. PROJECT NO.(If applicable) 6. ISSUED BY CODE W911QY 7. ADMINISTERED BY (If other than item 6) CODE S2206A W6QK ACC-APG NATICK DIVISION BLDG 1 GENERAL GREENE AVENUE NATICK MA 01760-5011 DEFENSE CONTRACT MAN |
|
| February 26, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation ModernaTX, Inc. Delaware Brizo Ltd. Bermuda Moderna Biotech Securities, Inc. Massachusetts Moderna Biotech UK Limited United Kingdom Moderna US, Inc. Delaware Moderna Services, Inc. Delaware Moderna France France Moderna Switzerland GmbH Switzerland Moderna Biotech Spain, S.L.U. Spain Moderna Biopharma Canada Corporation Canada Mod |
|
| February 25, 2021 |
EX-99.1 2 d118084dex991.htm EX-99.1 Exhibit 99.1 Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates 2021 Vaccine Manufacturing: Raises lower end of global manufacturing plan for 2021 from 600 million doses to 700 million doses; manufacturing is still working to supply up to 1 billion doses for 2021 2022 Vaccine Manufacturing: Based on the high deman |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Moderna, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 60770K 10 7 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934* (Amendment No. 2) Moderna, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 60770K 107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Moderna, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 60770K107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 10, 2021 |
Joint Filing Agreement between AstraZeneca PLC and Zeneca Inc. Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the common stock, $0. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Moderna Inc. Title of Class of Securities: Common Stock CUSIP Number: 60770K107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2021 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 4, 2021 |
January 4, 2021 Cambridge, Mass., USA EX-99.1 Exhibit 99.1 January 4, 2021 Cambridge, Mass., USA Dear fellow shareholders, By nearly all measures, 2020 was a historic year in our lives. It was also a historic year for Moderna. We started the year not knowing there was going to be a new virus, which would be declared a global pandemic—the first of its kind in 100 years since the Spanish flu. We ended the year with an Emergency Use Auth |
|
| December 23, 2020 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 21, 2020 |
EX-99.1 Exhibit 99.1 Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S. U.S. FDA authorizes mRNA vaccine against COVID-19 for emergency use Total of 200 million doses ordered by the U.S government to date; U.S. government retains option to purchase up to an additional 300 million doses Approximately 20 million doses will be delivered by the end of December 2020 Moderna intends |
|
| December 21, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 11, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 11, 2020 |
Exhibit 99.1 U.S. Government Exercises 1st Option for Additional 100 Million Doses of Moderna’s COVID-19 Vaccine Candidate Total of 200 million doses ordered by the U.S government to date Additional doses ordered today will be delivered in Q2 2021 U.S. government retains option to purchase up to an additional 300 million doses CAMBRIDGE, Mass.—December 11, 2020 – Moderna, Inc., (Nasdaq: MRNA) a bi |
|
| November 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 30, 2020 |
EX-99.1 Exhibit 99.1 Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization Primary efficacy analysis of the Phase 3 COVE study of mRNA-1273 involving 30,000 participants included 196 cases of COVID-19, of which 30 cases were severe Vaccine efficacy against COVID-19 was 94.1%; vaccine effic |
|
| November 16, 2020 |
EX-99.2 Exhibit 99.2 Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures Vaccine candidate now expected to remain stable at standard refrigerator temperatures of 2° to 8°C (36° to 46°F) for 30 days, up from previous estimate of 7 days Shipping and long-term storage conditions at standard freezer temperatures of -20°C (-4°F) for 6 months mRNA-1273 to |
|
| November 16, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 16, 2020 |
EX-99.1 Exhibit 99.1 Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study First interim analysis included 95 participants with confirmed cases of COVID-19 Phase 3 study met statistical criteria with a vaccine efficacy of 94.5% (p <0.0001) Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in t |
|
| October 30, 2020 |
EX-10.1 2 exhibit101.htm EX-10.1 EXHIBIT 10.1 Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH "[***]". SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Table of Contents PA |
|
| October 30, 2020 |
exhibit103 EXHIBIT 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 1. THIS CONTRACT IS A RATED ORDER RATING PAGE OF PAGES AWARD/CONTRACT UNDER DPAS (15 CFR 700) 1 53 2. CONTRACT (Proc |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| October 30, 2020 |
EXHIBIT 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. CONFIDENTIAL GLOBAL LONG TERM AGREEMENT This Global Long Term Agreement is made as of September 4, 2020, and effective as of Ma |
|
| October 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 29, 2020 |
EX-99.1 Exhibit 99.1 Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates Phase 3 study of COVID-19 vaccine candidate (mRNA-1273) fully enrolled with 30,000 participants, including 37% from diverse communities and 42% at high-risk of severe disease (>65 years or co-morbid risk factors) Positive interim data from Phase 2 study of CMV vaccine candidate (mRNA-1647) annou |
|
| September 18, 2020 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 12, 2020 |
EX-99.1 Exhibit 99.1 Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) New U.S. government award up to $1.525 billion for 100 million doses Option granted to U.S. government to purchase up to an additional 400 million doses CAMBRIDGE, Mass.—August 11, 2020 – Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pionee |
|
| August 6, 2020 |
bardav3 EXHIBIT 10.1 Contract No. 75A50120C00034 Development of an mRNA Vaccine for SARS-CoV-2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Table of Contents PART I – THE SCHEDULE ..... |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| August 6, 2020 |
Offer Letter by and between the Company and David W. Meline, dated as of June 3, 2020 exhibit1026302020 EXHIBIT 10.2 June 2, 2020 David Meline [***] [***] Re: Offer of Employment by ModernaTX, Inc. Dear David, ModernaTX, Inc. (the “Company”) is pleased to confirm, contingent on receiving appropriate references and the successful completion of a background check/drug screen, its offer to employ you as Chief Financial Officer, reporting to the Chief Executive Officer. Your effective |
|
| August 5, 2020 |
EX-99.1 Exhibit 99.1 Moderna Reports Second Quarter 2020 Financial Results and Provides Business Updates Ended quarter with $3.1 billion in cash, cash equivalents and investments Moderna has received approximately $400 million of customer deposits as of July 31, 2020 for potential supply of mRNA-1273 Moderna updates 2020 guidance to reflect investments into mRNA-1273; the Company now expects net c |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 31, 2020 |
Moderna Announces Resignation of Dr. Elizabeth Nabel from Board of Directors EX-99.1 Exhibit 99.1 Moderna Announces Resignation of Dr. Elizabeth Nabel from Board of Directors CAMBRIDGE, Mass.—July 30, 2020 – Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the resignation of Elizabeth (Betsy) Nabel, M.D., from Mo |
|
| July 29, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 29, 2020 |
EX-99.1 Exhibit 99.1 Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273) mRNA-1273 induced robust neutralizing antibodies and dose dependent increases in T cell responses mRNA-1273 led to protection against SARS-CoV-2 infection in the lungs and nose of non-human primates No evid |
|
| July 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 27, 2020 |
EX-99.1 Exhibit 99.1 Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19 Additional funding to support expanded mRNA-1273 clinical development plan including 30,000 participant Phase 3 COVE study conducted in collaboration with the NIH CAMBRIDGE, Mass.—July 26, 2020— Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology c |
|
| July 15, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 15, 2020 |
EX-99.1 Exhibit 99.1 Moderna Announces Publication in The New England Journal of Medicine of Interim Results from Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273) Interim analysis of original cohorts of Phase 1 study evaluated two-dose vaccination schedule of mRNA-1273 across three dose levels (25, 100, 250 µg) in 45 healthy adults ages 18-55 years; results reaffirm and expand upon p |
|
| July 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commi |
|
| June 4, 2020 |
David Meline Joins Moderna as Chief Financial Officer EX-99.1 Exhibit 99.1 David Meline Joins Moderna as Chief Financial Officer CAMBRIDGE, Mass., June 4, 2020 — Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that David Meline has joined Moderna as Chief Financial Officer, effective Monda |
|
| June 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 20, 2020 |
Moderna Announces Pricing of Public Offering of Shares of Common Stock EX-99.1 Exhibit 99.1 Moderna Announces Pricing of Public Offering of Shares of Common Stock CAMBRIDGE, Mass., May 18, 2020 — Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the pricing of an underwritten public offering of 17,600,000 sh |
|
| May 20, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 20, 2020 |
424B5 Table of Contents CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Amount to be Registered(1) Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0. |
|
| May 20, 2020 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION 17,600,000 Shares MODERNA, INC. COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT May 18, 2020 May 18, 2020 Morgan Stanley & Co. LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Moderna, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Sched |
|
| May 18, 2020 |
EX-99.1 Exhibit 99.1 Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus After two doses all participants evaluated to date across the 25 µg and 100 µg dose cohorts seroconverted with binding antibody levels at or above levels seen in convalescent sera mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants acro |
|
| May 18, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 18, 2020 Registration No. |
|
| May 18, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 15, 2020 |
EX-99.1 Exhibit 99.1 Moderna Congratulates Dr. Moncef Slaoui on His Appointment to Oversee the White House’s Operation Warp Speed Initiative CAMBRIDGE, Mass.—May 15, 2020 – Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Dr. Moncef |
|
| May 7, 2020 |
EX-99.1 Exhibit 99.1 Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates Progress on novel coronavirus vaccine (mRNA-1273) includes FDA clearance to proceed with Phase 2 study Finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020 Awarded up to $483 million funding from BARDA for accelerated development of mRNA-1273 Entered stra |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38753 Moderna, Inc. |
|
| May 7, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38753 81-3467528 (State or other jurisdiction of incorporation) (Commission File Numb |
